OncoCyte Corporation (0KCC.L)

2,4900 -0,1350 (-5,14%) In data: 03:26PM BST. Mercato aperto.

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://oncocyte.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joshua Riggs	President, CEO & Director	373,2k	N/D	1983
Mr. James Liu	Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer	192,48k	N/D	1996
Dr. Ekkehard Schutz M.D., Ph.D.	Chief Science Officer	N/D	N/D	N/D
Mr. Peter Hong	VP, General Counsel & Secretary	N/D	N/D	N/D
Mr. Yuh-Min Chiang Ph.D.	Senior Vice President of R&D and Product Development	N/D	N/D	N/D
Ms. Sandra O'Donald	Senior Vice President of Business Operations	N/D	N/D	N/D
Dr. Michael D. West Ph.D.	Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.	N/D	N/D	1953
Ms. Sara Riordan	Director of Medical Education	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Governance aziendale

L'ISS Governance QualityScore di OncoCyte Corporation al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.